Evidence regarding SGLT2 inhibitors for the management of diabetic dyslipidemia

We read with interest the article by Puri et al. entitled, “Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of India”. The article states that more than half of the patients with diabetes have a high risk of dyslipidemia, resulting in an accelerated risk of atherosclerotic cardiovascular disease (ASCVD). The authors thereby release a consensus statement from the Lipid Association of India (LAI) for the management of diabetic dyslipidemia. This statement discusses the effects of lipid lowering drugs such as statins/ezetimibe, sodium-glucose transport protein 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for diabetic dyslipidemia. 1 Puri R. Mehta V. Duell P.B. Wangnoo S.K. Rastogi A. Mohan V. et al. Management of diabetic dyslipidemia in Indians: expert consensus statement from the Lipid Association of India. J Clin Lipidol [Internet]. 2022 Nov; ([cited 2022 Dec 27];0(0). Available from:)http://www.lipidjournal.com/article/S1933287422003002/fulltext Google Scholar Management of diabetic dyslipidemia in Indians: Expert consensus statement from the Lipid Association of IndiaJournal of Clinical LipidologyVol. 17Issue 2PreviewAn estimated 537 million adults aged 20–79 years worldwide have diabetes mellitus, almost all type 2 diabetes.1 In India, the burden of diabetes has been increasing steadily since 1990 but the pace accelerated after the year 2000, resulting in an increase in the prevalence of diabetes from 7.1% to 8.9% between 2009 and 2019. It is estimated that the number of individuals with diabetes in India will increase from 74 million in 2021 to more than 125 million in 2045,1 primarily driven by increasing rates of elevated body mass index (BMI) and the metabolic syndrome in association with visceral adiposity. Full-Text PDF Evidence regarding SGLT-2 inhibitors for the management of diabetic dyslipidemiaJournal of Clinical LipidologyVol. 17Issue 3PreviewWe thank doctors Seetharaman and Joshi for their interest in our recently published Expert Consensus Statement on Management of Diabetic Dyslipidemia in Indians from the Lipid Association of India.1 They have expressed concerns about possible adverse effects of treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors on the concentration of low-density lipoprotein cholesterol (LDL-C) in plasma. Full-Text PDF